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Edited by Barry HalliwellAbstract Administration of interleukin-15 (IL-15) to rats
bearing the Yoshida AH-130 ascites hepatoma (a tumour that
induces an important cachectic response) resulted in a signiﬁcant
reduction of muscle wasting, both measured as muscle weight
and as protein content of diﬀerent types of skeletal muscle. In
addition, the administration of the cytokine completely reversed
the increased DNA fragmentation observed in skeletal muscle of
tumour-bearing animals. Concerning the mechanism(s) involved
in the anti-apoptotic eﬀects of IL-15 on skeletal muscle, the
administration of the cytokine resulted in a considerable
decrease in both R1 (43%) and R2 (64%) TNF-a receptors
(TNFRs), and therefore it may be suggested that IL-15
decreases apoptosis by aﬀecting TNF-a signalling. Formation
of NO could be the signalling event associated with the activation
of apoptosis in muscle of tumour-bearing rats; indeed, adminis-
tration of IL-15 decreased the inducible nitric oxide synthase
protein levels by 73%, suggesting that NO formation and muscle
apoptosis during tumour growth are related. In conclusion, IL-15
seems to be able to reduce/suppress protein loss and apoptosis
related to muscle wasting during cancer cachexia in experimen-
tal animals.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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In addition to its role as T-cell proliferation factor [1], in-
terleukin-15 (IL-15) has considerable metabolic eﬀects in-
volving both adipose tissue and skeletal muscle. Indeed, IL-15
depletes fat tissue by inhibiting both lipoprotein lipase activity
and de novo lipogenesis [2]. Interestingly, the eﬀects of the
cytokine on adipose tissue seem to be direct, the presence of
the diﬀerent receptor subunits having been reported in adipose
tissue [2].
IL-15 also exerts important eﬀects in skeletal muscle, where
it behaves as an anabolic cytokine both in vitro [3] and in vivo
[4]. Indeed, addition of the cytokine to muscle cell cultures
increases the expression of the myosin heavy-chain together
with total myoﬁbrillar content [3]. Interestingly, IL-15 exerts* Corresponding author. Fax: +34-9340-21559.
E-mail address: fsoriano@porthos.bio.ub.es (F.J. Lopez-Soriano).
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doi:10.1016/j.febslet.2004.05.066its eﬀects in muscle cells by both decreasing the rate of protein
degradation and increasing the rate of proliferation [3]. Pre-
vious work from our laboratory has shown that administration
of IL-15 to cachectic tumour-bearing animals results in an
amelioration of the muscle wasting. IL-15 decreases the ac-
tivity of the ubiquitin/proteasome pathway (the main proteo-
lytic pathway activated during cancer cachexia) in skeletal
muscle of tumour-bearing animals [5]. In addition to increase
muscle protein degradation during cancer growth, the presence
of the tumour also induces an increased rate of DNA frag-
mentation in skeletal muscle both in rats and mice [6]. This
increased rate of fragmentation seems to be activated by tu-
mour necrosis factor-a (TNF-a) [7].
IL-15 has been shown to be anti-apoptotic in diﬀerent cell
types [8–10]. Bearing this in mind, the main aim of the present
study was to investigate if administration of IL-15 to cachectic
tumour-bearing animals could reduce/neutralize the increased
apoptotic rate previously observed in skeletal muscle of tu-
mour-bearing animals.2. Materials and methods
2.1. Animals, tumour inoculation and treatment
Male Wistar rats (Interfauna, Barcelona, Spain) weighing approxi-
mately 110–135 g were used. The animals were maintained on a regular
light–dark cycle (lights on from 8:00 a.m. to 8:00 p.m.) and had free
access to food and water. The diet consisted of 54% carbohydrate, 17%
protein and 5% fat (the residue was non-digestible material). Rats were
divided into two groups, controls and tumour hosts. The latter re-
ceived an intraperitoneal inoculum of 108 AH-130 Yoshida ascites
hepatoma cells obtained from exponential tumours [11]. Both groups
were further divided into treated and untreated, the former being ad-
ministered a daily s.c. dose of IL-15 (100 lg kg1 b.w. dissolved in
physiological saline solution), the latter a corresponding volume of
vehicle. Recombinant human IL-15 was kindly provided by Immunex
Corporation (Seattle, WA, USA).
On day 7 after the tumour transplantation, animals were weighed
and anaesthesized with ketamine:xylacine. The tumour was harvested
from the peritoneal cavity, its volume and cellularity evaluated. Tissues
were rapidly excised, weighed, and frozen in liquid nitrogen [11,12].
2.2. RNA isolation and Northern blot analysis
Total RNA from gastrocnemius (GSN) muscles was extracted using
the acid guanidinium isothiocyanate/phenol/chloroform method as
described by Chomczynski and Sacchi [13]. RNA samples (20 lg) were
denatured, subjected to 1.2% agarose gel electrophoresis and trans-
ferred to Hybond N membrane (Amersham). RNA was ﬁxed to the
membranes by Genelinker (BioRad). The RNA in gel and ﬁlters
was visualized with ethidium bromide and photographed by UVblished by Elsevier B.V. All rights reserved.
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of the equivalent amounts of RNA and to conﬁrm proper transfer.
RNA was transferred in 20X standard saline citrate (SSC: 0.15 M
NaCl and 15 mM sodium citrate, pH 7.0). Hybridization was done at
65 C overnight in the hybridization buﬀer (0.25 M Na2HPO4, 7%
SDS, 1 mM EDTA, 1% BSA, and 10% dextran sulfate) and denatured
labelled probes (106–107 cpmml1) were added. Radiolabelled probes
were prepared by random priming method (Roche). The probes used
were the entire coding frame for mouse UCP2 [14], a cDNA clone
containing the entire coding frame for mouse UCP3 (D.S. Fleury, C.F.
Bouillard, GenBank Accession No. AF032902), Bax was generated by
PCR (Accession No. U49729), and a 18S rat ribosomal probe was used
as hybridization/quantiﬁcation standard. Blots were quantiﬁed on a
phosphoimager using the Phoretix 1 D gel analysis (Phoretix Int. Ltd.,
England).3. RT-PCR
Analysis of mRNA levels for TNF-a, TNFR1, TNFR2 and
Bcl-2 were performed with primers designed to detect gene
products. TNF-a used primers 50-TACTGAACTTCGGG-
GTGATTGGTC-30 and 50-CAGCCTTGTCCCTTGAAGA-
GAACC-30, resulting in a 298-bp product. TNFR1 used
primers 50-CCTGATTTCCATCTACCTCTGACTTTGAGC-
30 and 50-ACACTGGAAATGCGTCTCACTCAGGTAGC-
G-30, resulting in a 594-bp product. TNFR2 used primers
50-GATGAGAAATCCCAGGATGCAGTAGG-30 and 50-
GCTACAGACGTTCACGATGCAGG-30, generating a 256-
bp fragment. Bcl-2 used primers 50-CTGTACGGCCCCAG-
CATGCG-30 and 50-GCTTTGTTTCATGGTACATC -30,
resulting in a 231-bp product. 18S was used as a control of
loading and the primers are 50-CGCAGAATTCCCACT-
CCCGACCC-30 and 50-CCCAAGCTCCAACTACGAGC-30,
resulting in a 212-bp product. RT-PCRs were performed with
0.4 lg of total RNA by a one-step RT-PCR method (Ready-
to-GoTM RT-PCR Beads, Amersham Biosciences) as follows:
TNF-a: 1 (42 C, 30 min); 1 (92 C, 2 min); 1 (94 C, 1
min); 32 (94 C, 1:30 min; 60 C, 1 min; 72 C, 2 min); 1 (72
C, 4 min). TNFR1: 1 (42 C, 30 min); 1 (92 C, 2 min); 1
(94 C, 1 min); 30 (94 C, 30 s; 60 C, 30 s; 72 C, 45 s); 1
(72 C, 7 min). TNFR2: 1 (42 C, 30 min); 1 (92 C, 2 min);
1 (94 C, 3 min); 31 (94 C, 45 s; 60 C, 30 s; 72 C, 1:30
min); 1 72 C, 10 min. Bcl-2: 1 (42 C, 30 min); 1 (92 C, 2
min); 25 (95 C, 1 min; 55 C, 1 min; 72 C, 2 min); 1 (72
C, 7 min). 18S: 1 (42 C, 30 min); 1 (92 C, 2 min); 10 (92
C, 30 s; 55 C, 1 min; 72 C, 2 min); 1 (72 C, 7 min).
The RT-PCR products were electrophoresed in 2% agarose
gels in TBE buﬀer. The gel was stained with ethidium bromide
and quantiﬁed by scanning densitometry. Values for TNF-a,
TNFRs and Bcl-2 mRNA were corrected by 18S RNA ex-
pression and expressed as percentage.
3.1. DNA fragmentation assay
GSN muscles were homogenized and incubated at 48 C
overnight in Kauﬀman buﬀer (0.5 M Tris, 2 mM EDTA, 10
mM NaCl, and 1% SDS) in the presence of 200 lg ml1 of
proteinase K, and DNA was extracted with phenol/chloro-
form. After ethanol precipitation, the pellets were resuspended
and the DNA integrity was checked in a 2% agarose gel elec-
trophoresis and ethidium bromide staining. The percentage of
DNA fragmentation was quantiﬁed by scanning densitometry.
Liver from 8-h anti-Fas antibody-treated mice [15] was used as
a positive control of DNA fragmentation.3.2. Immunoblotting
GSN frozen muscle samples were homogenized in 6 v/w ice-
cooled homogenization buﬀer A (10 mM Tris-maleate, 3 mM
EGTA, 275 mM sucrose, 0.1 mM DTT; 2 lg/ml leupeptin; 100
lg/ml PMSF; 2 lg/ml aprotinin, 1 mg/100 ml pepstatin A, pH
7.2). Samples were then centrifuged at 1000g for 30 min. The
pellet was discarded and the supernatant was designated as
crude homogenate. Total muscle protein level in each sample
was determined with the Bradford technique (BioRad Inc.,
Hercules, CA). Crude muscle homogenates (100 lg per sam-
ple) were separated by electrophoresis, transferred to polyv-
inylidene diﬂuoride membranes, blocked with non-fat milk
and incubated overnight with the selective anti-iNOS antibody
(Transduction Laboratories Inc., Lexington, KY). To validate
equal protein loading among various lanes, PVDF membranes
were stripped and re-probed with a monoclonal anti-tubuline
antibody (Sigma, St. Louis, MO, USA). Lysates obtained from
cytokine-activated macrophages and septic rat diaphragm
homogenates were used as positive controls for iNOS protein
expression. Speciﬁc proteins were detected with horseradish
peroxidase (HRP)-conjugated secondary antibodies and a
chemiluminescence kit. Blots were scanned with an imaging
densitometer and optical densities (OD) of a 130 kDa protein
were quantiﬁed with the software Diversity database 2.1.1
(BioRad Laboratories, Philadelphia, PA) from all the samples.
3.3. Statistical analysis
Statistical analysis of the data was performed by means of
one-way analysis of variance (ANOVA).4. Results and discussion
The implantation of the rapidly growing tumour Yoshida
AH-130 resulted in a decrease of liver (40%), white adipose
tissue (WAT) (71%) and carcass weight (39%) (Table 1). Ad-
ministration of IL-15 to tumour-bearing rats promoted a sig-
niﬁcant increase in liver and carcass weights, while no changes
were observed concerning WAT (Table 1). Administration of
the cytokine did not result in any changes in tumour cell
content. IL-15 treatment promoted a signiﬁcant decrease in
liver weight (9%) and WAT (36%) in non-tumour-bearing
animals (Table 1). This result has been reported previously, IL-
15 decreasing WAT mass by inhibiting fatty acid synthesis in
the adipocyte [16].
Tumour burden inﬂicted an important decrease in muscle
weights: GSN (35%), soleus (28%), tibialis (35%) and heart
(32%) (Table 1). Interestingly, administration of the cytokine
was able to partially revert the decrease in muscle weights in-
ﬂicted by the presence of the tumour (Table 1). No eﬀects of
the cytokine were observed on the muscle weights of non-tu-
mour-bearing animals (Table 1). These results support previ-
ous studies [5] clearly demonstrating that IL-15 does indeed act
as an anabolic cytokine on skeletal muscle. The mechanism
associated with the eﬀects of the cytokine on muscle involves a
decrease in the rate of protein degradation, as previously de-
scribed [5].
Previous studies from our laboratory indicated that, during
experimental cancer cachexia, increased DNA fragmentation
could be observed in skeletal muscle, suggesting that protein
wasting in the muscle mass is accompanied by an active ap-
optotic process [7]. Bearing this in mind, we decided to test if
Fig. 1. DNA fragmentation in GSNmuscles from tumour-bearing rats.
For more details, see Section 2. Results are means S.E.M. for ﬁve
diﬀerent animals in each experimental group. DNA fragmentation was
assessed by monitoring the laddering in an agarose gel. C, control; CT,
control treated; T, tumour; TT, tumour treated. Statistical signiﬁcance
of the results by one-way ANOVA, between groups: P ¼ 0:0002; dif-
ferent superscripts indicate signiﬁcant diﬀerences between groups by
post-hoc Duncan test.
Table 1
Body and tissue weights
C CT T TT ANOVA
(4) (4) (5) (6)
IBW 111 3 111 3 115 4 114 3 ns
Muscle weights
GSN 683 13a 677 13a 442 13b 489 7c P < 0:001
Tibialis 215 3a 206 5a 140 4b 163 3c P < 0:001
Soleus 52.0 0.3a 55.6 1.3b 37.5 1.0c 42.1 0.9d P < 0:001
Heart 532 14a 524 5a 360 13b 387 6b P < 0:001
Liver 7944 123a 7196 56b 4098 105c 4769 200d P < 0:001
WAT 838 54a 539 52b 269 30c 246 21c P < 0:001
Carcass 108 1a 104 1b 66 1c 72 1d P < 0:001
Tumour cell content 4528 156 4895 312 ns
Tumour volume 54 2 57 3 ns
Results are meansS.E.M. for the number of animals indicated in brackets. Initial body weight (IBW) is expressed in grams. Tissue weights are
expressed as mg per 100 g of IBW. Tumour cell content is expressed in millions of cells. Tumour volume is expressed in ml. GSN, gastrocnemius;
WAT, white adipose tissue; C, control; CT, control-treated; T, tumour; TT, tumour-treated. Statistical signiﬁcance of the results by one-way
ANOVA; diﬀerent superscripts indicate signiﬁcant diﬀerences between groups by post-hoc Duncan test. ns, non-signiﬁcant diﬀerences.
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tosis. Previously, it has been shown that IL-15 behaves like an
anti-apoptotic cytokine in immune cells [8–10,17]. However,
the anti-apoptotic mechanism is still far from being under-
stood [8,17].
The results presented in Fig. 1 clearly show that tumour
growth induced an active skeletal muscle DNA fragmentation.
Very interestingly, in the animals treated with IL-15 the eﬀect
of tumour burden on DNA fragmentation was abolished,
therefore suggesting that the anti-apoptotic eﬀects of IL-15 can
be extended to muscle tissue. We also analyzed the gene ex-
pression of Bcl-2 (an anti-apoptotic protein) and Bax (a
proapoptotic protein) in skeletal muscle of tumour-bearing
rats. The results presented in Fig. 2 show that both markers
were signiﬁcantly increased (80% for Bax, 61% for Bcl-2) in
GSN muscles of tumour-bearing rats as compared with the
non tumour-bearing animals. Interestingly, IL-15 treatment
decreased both Bax (64%) and Bcl-2 (50%) mRNA levels in
tumour-bearing rats (Fig. 2). In fact, the presence of the tu-
mour results in an increase in the Bax/Bcl-2 ratio, suggesting
an increase in proapoptotic activity (Fig. 2). Cytokine treat-
ment completely reverses the increased ratio (Fig. 2).
In tumour-bearing rats, one of the signals that seems to
activate the apoptotic process in skeletal muscle is the cytokine
TNF-a. Indeed, in animals chronically treated with TNF-a
there is an increased DNA fragmentation in skeletal muscle [7].
Similarly, TNFR1-deﬁcient mice do not show an increased
rate of DNA fragmentation in skeletal muscle when the ani-
mals were inoculated with the cachetic Lewis lung carcinoma
[7]. Indeed, TNF-a behaves like a clear apoptotic signal in
numerous cell types [18,19], the apoptotic cascade involving
speciﬁcally TNFR1 [18,20]. Bearing this in mind, we decided to
analyze whether IL-15 exerts apoptotic eﬀects by altering
TNF-a signalling in skeletal muscle. As can be seen in Fig. 3,
the presence of the tumour induced an important increase in
TNFR1 (49%) and TNFR2 (71%), while the expression of the
cytokine was signiﬁcantly decreased (73%). Interestingly, the
administration of IL-15 completely reversed the increased
mRNA content of TNFRs in skeletal muscle of tumour-
bearing rats, while no changes were observed in TNF-a
mRNA content in IL-15-treated rats (Fig. 3). These results
suggest that the anti-apoptotic mechanism of IL-15 involves a
downregulation of TNFRs in skeletal muscle.One of the major ﬁndings of the present study is that sys-
temic administration of IL-15 to the rats markedly reduced
protein levels of the inducible nitric oxide synthase (iNOS) in
GSN muscles of the cachectic group of animals. The proin-
ﬂammatory cytokine TNF-a was shown to induce apoptosis
via iNOS expression and nitric oxide (NO) production in
neonatal cardiomyocytes [21]. Conversely, the absence of
iNOS enzyme in those cells (iNOS deﬁcient mice) led to a
dramatic reduction in the TNF-a-induced apoptosis. It has
been also pointed out that oxidative stress could be involved in
Fig. 2. Expression of Bcl-2 and Bax in skeletal muscle of tumour-bearing rats. For more details, see Section 2. Results are expressed as means
S.E.M. for n ¼ 4 and 6 for non-tumour and tumour-bearers, respectively. C, control; CT, control-treated; T, tumour; TT, tumour-treated. Statistical
signiﬁcance of the results by one-way ANOVA, P ¼ 0:0003 (Bax), P ¼ 0:0008 (Bcl-2) and P ¼ 0:0412 (Bax/Bcl-2); diﬀerent superscripts indicate
signiﬁcant diﬀerences between groups by post-hoc Duncan test.
Fig. 3. Expression of TNF-a and its receptors in GSN muscles from rats bearing the Yoshida AH-130 ascites hepatoma. For more details, see Section
2. Results are expressed as meansS.E.M. for n ¼ 4 and 6 for non-tumour and tumour-bearers, respectively. RT-PCR electrophoresis of GSN
muscle samples showing the diﬀerent bands corresponding to TNF-a and its receptors and quantiﬁcation of both TNF-a and its receptors in skeletal
muscle on tumour-bearing rats. C, control; CT, control-treated; T, tumour; TT, tumour-treated. Statistical signiﬁcance of the results by one-way
ANOVA, P ¼ 0:0001 (TNF-a), P ¼ 0:0689 (TNFR1) and P ¼ 0:0176 (TNFR2); diﬀerent superscripts indicate signiﬁcant diﬀerences between groups
by post-hoc Duncan test.
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and has been related with the muscle wasting during cancer
cachexia [23]. Under normal conditions, NO is usually syn-
thesized by the neuronal NO synthase (nNOS) within the
skeletal muscle ﬁbre. However, the iNOS is by far the most
important contributor to NO production under inﬂammatory
conditions provided that this enzyme also bears the highest
rate of NO synthesis as compared to the constitutive isoforms.
One of the most potent and well known molecules capable of
increasing iNOS expression is TNF-a through binding to its
receptors (TNFRs) 1 and 2, via the activation of the NF-jB
transcription factor. Taking this into consideration, we de-
cided to analyze the content of iNOS, the main enzyme that
participates in NO formation. The results presented in Fig. 4
demonstrate that tumour burden increased iNOS (81%) in
skeletal muscle. Very interestingly, administration of IL-15
reverted the increased iNOS protein content, suggesting that
this enzyme is also involved in the anti-apoptotic signalling
cascade associated with the cytokine (Fig. 4). Accordingly,Fig. 4. iNOS protein levels in skeletal muscle of Yoshida AH-130
bearing rats. For more details, see Section 2. Results are expressed as
meansS.E.M. for n ¼ 4 animals. C+, positive control; C, control;
CT, control-treated; T, tumour; TT, tumour-treated. Statistical sig-
niﬁcance of the results by one-way ANOVA, between groups:
P ¼ 0:0308; diﬀerent superscripts indicate signiﬁcant diﬀerences be-
tween groups by post-hoc Duncan test.
Table 2
Expression of uncoupling proteins in skeletal muscle of tumour-bearing rats
Experimental group IL-15 treatment UC
Control No 100
Yes 83
Tumour No 114
Yes 162
ANOVA (P) 0.0
Expression of the UCP2 and UCP3 mRNAs was detected after hybridization
blots with the rat 18S ribosomal subunit probe. Autoradiographs were subject
5 for non-tumour and tumour-bearers, respectively. Statistical signiﬁcance
signiﬁcant diﬀerences between groups by post-hoc Duncan test.based on the increased mRNA expression of both TNFR1 and
TNFR2, we conclude from our study that one possible
mechanism to account for the augmented DNA fragmentation
present in the muscle ﬁbres of tumour-bearing animals is the
increased TNF-a-mediated iNOS enzyme content induction.
Interestingly, IL-15 administration induced a marked reduc-
tion in iNOS protein content only within the muscle ﬁbres of
the cachectic animals, showing no change regarding its protein
levels in the ﬁbres of those IL-15-treated control rats. One
likely explanation of the involvement of iNOS in muscle ap-
optosis is that excessive NO synthesis in cancer cachectic
muscles would lead to the formation of the highly reactive
oxygen species (ROS) peroxynitrite, developing nitrosative
stress [24].
Uncoupling proteins (UCPs) have been associated with the
disruption of the proton gradient across the inner mitochon-
drial membrane, therefore having a potential energy-dissipat-
ing role [25,26]; however, other functions for these proteins
have been reported [27]. Among these functions, a role as a
mechanism for a compensating oxidative stress has been de-
scribed [28,29]. Indeed, uncoupling the respiratory chain from
oxidative phosphorylation results in less ROS formation. On
these lines, several studies conﬁrm that an increase in UCP2
gene expression is related to a decreased generation of H2O2
[30]. In fact, UCP2 induction has been suggested as a counter-
mechanism in pathophysiological conditions leading to in-
creased oxidative stress [31–33].
Taking all this into consideration, it is very interesting to
analyze the eﬀects of IL-15 treatment on the expression of
these uncoupling proteins. Indeed, as can be seen in Table 2,
tumour growth induced an increase in the expression of these
proteins in skeletal muscle, both UCP2 (12%) and UCP3
(67%). Administration of IL-15 promoted an increased ex-
pression on both UCP2 (30%) and UCP3 (22%) in tumour-
bearing rats, again suggesting that the mechanism associated
with the anti-apoptotic action of IL-15 could well involve
TNF-a signalling since IL-15 is able to inﬂuence TNFRs
content in skeletal muscle. Additionally, the cytokine could
exert its eﬀects by decreasing oxidative stress, possibly by in-
ﬂuencing content (and activity) of uncoupling proteins in
skeletal muscle.
In conclusion, from the results presented here it can be
suggested that IL-15, in addition to partially reverting muscle
wasting associated with tumour-growth, completely reverts the
increased DNA fragmentation observed in skeletal muscle of
tumour-bearing animals. This makes the cytokine a potentially
important drug for the treatment of muscle wasting associated
with neoplasies.P 2 UCP 3
 8a 100 18a
 13a 115 34a
 13a 298 35b
 10b 381 23c
011 <0.001
with cDNA probes. Loading correction was carried out by performing
ed to scanning densitometry. Results are meansS.E.M. for n ¼ 6 and
of the results by one-way ANOVA; diﬀerent superscripts indicate
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